Office Management after Myocardial Infarction

  • Wilbert S. Aronow
    Requests for reprints should be addressed to Wilbert S. Aronow, MD, FACC, FAHA, Cardiology Division, New York Medical College, Macy Pavilion, Room 138, Valhalla, NY 10595
    Department of Medicine, Divisions of Cardiology, Geriatrics, and Pulmonary/Critical Care, New York Medical College, Valhalla, New York
    Search for articles by this author


      Patients should have their modifiable coronary artery risk factors intensively treated after myocardial infarction. Hypertension should be treated with beta-blockers and angiotensin-converting enzyme inhibitors. The blood pressure should be reduced to less than 140/90 mm Hg or to less than 130/80 mm Hg in patients with diabetes or chronic kidney disease. The serum low-density lipoprotein cholesterol should be reduced to less than 70 mg/dL with statins if necessary. Diabetic patients should have their hemoglobin A1c reduced to less than 7.0%. Aspirin or clopidogrel, beta-blockers, and angiotensin-converting enzyme inhibitors should be given indefinitely unless contraindications exist to their use. Long-acting nitrates are effective anti-anginal and anti-ischemic drugs. After an infarction, patients at very high risk for sudden cardiac death should receive an implantable cardioverter-defibrillator. The 2 indications for coronary revascularization are prolongation of life and relief of unacceptable symptoms despite optimal medical management.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to The American Journal of Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Smith Jr, S.C.
        • Allen J.
        • Blair S.N.
        • et al.
        ACC/AHA guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute.
        Circulation. 2006; 113: 2363-2372
        • 2003 Joint National Committee
        The Seventh Report of the Joint National Committee on the Detection, Evaluation, and Treatment of High Blood Pressure (JNC VII).
        JAMA. 2003; 289: 2560-2572
        • HOPE (Heart Outcomes Prevention Evaluation) Study Investigators
        Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.
        N Engl J Med. 2000; 342: 145-153
        • Rosendorff C.
        • Black H.R.
        • Cannon C.P.
        • et al.
        Treatment of hypertension in the prevention and management of ischemic heart disease.
        Circulation. 2007; 115: 2761-2788
        • Heart Protection Study Collaborative Group
        MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.
        Lancet. 2002; 360: 7-22
        • Grundy S.M.
        • Cleeman J.I.
        • Merz C.N.
        • et al.
        Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.
        Circulation. 2004; 110: 227-239
        • Ades P.A.
        Exercise training and cardiac rehabilitation in older cardiac patients.
        in: Aronow W.S. Fleg J.L. Rich M.W. Cardiovascular Disease in the Elderly. Fourth edition. Informa Healthcare, New York City2008: 405-417
        • Smith Jr, S.C.
        • Blair S.N.
        • Bonow R.O.
        • et al.
        AHA/ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update.
        J Am Coll Cardiol. 2001; 38: 1581-1583
        • Aronow W.S.
        • Frishman W.H.
        Angina in the elderly.
        in: Aronow W.S. Fleg J. Rich M.W. Cardiovascular Disease in the Elderly. Fourth edition. Informa Healthcare, New York City2008: 269-292
        • Teo K.K.
        • Yusuf S.
        • Furberg C.D.
        Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction.
        JAMA. 1993; 270: 1589-1595
        • Julian D.G.
        • Camm A.J.
        • Frangin G.
        • et al.
        Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT.
        Lancet. 1997; 349: 667-674
        • Kennedy H.L.
        • Brooks M.M.
        • Barker A.H.
        • et al.
        Beta-blocker therapy in the Cardiac Arrhythmia Suppression Trial.
        Am J Cardiol. 1994; 74: 674-680
        • Aronow W.S.
        • Ahn C.
        • Mercando A.D.
        • et al.
        Effect of propranolol versus no antiarrhythmic drug on sudden cardiac death, total cardiac death, and total death in patients ≥62 years of age with heart disease, complex ventricular arrhythmias, and left ventricular ejection fraction ≥40%.
        Am J Cardiol. 1994; 74: 267-270
        • The Antiarrhythmics Versus Implantable Defibrillators (AVID) Investigators
        A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias.
        N Engl J Med. 1997; 337: 1576-1583
        • Moss A.J.
        • Zareba W.
        • Hall W.J.
        • et al.
        Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
        N Engl J Med. 2002; 346: 877-883
        • Davis M.M.
        • Taubert K.
        • Benin A.L.
        • et al.
        Influenza vaccination as secondary prevention for cardiovascular disease: a science advisory from the American Heart Association/American College of Cardiology.
        J Am Coll Cardiol. 2006; 48: 1498-1502
        • Holmes Jr, D.R.
        • Singh M.
        Percutaneous coronary intervention in the elderly.
        in: Aronow W.S. Fleg J. Rich M.W. Cardiovascular Disease in the Elderly. Fourth edition. Informa Healthcare, New York City2008: 387-404
        • Stemmer E.A.
        • Aronow W.S.
        Surgical management of coronary artery disease in the elderly.
        in: Aronow W.S. Fleg J. Rich M.W. Cardiovascular Disease in the Elderly. Fourth edition. Informa Healthcare, New York City2008: 351-385